Skip to main content
Jashin Wu, MD, Dermatology, Irvine, CA

JashinJoaquinWuMD

Dermatology Irvine, CA

Founder and CEO, Dermatology Research and Education Foundation

Dr. Wu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Wu's full profile

Already have an account?

Education & Training

  • University of California (Irvine)
    University of California (Irvine)Residency, Dermatology, 2005 - 2008
  • Baylor College of Medicine
    Baylor College of MedicineInternship, Internal Medicine, 2002 - 2003
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 2002

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2004 - 2024
  • TX State Medical License
    TX State Medical License 2003 - 2004
  • American Board of Dermatology Dermatology

Awards, Honors, & Recognition

  • Fellow (FAAD) American Academy of Dermatology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis  
    Andrew Blauvelt, Craig L Leonardi, Jashin J Wu, JAMA Dermatology
  • Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis from the Medical Board of the National Psoriasis Foundation  
    Ronald Prussick, Johann E Gudjonsson, Alice Gottlieb, John Koo, Jerry Bagel, Adam R Ford, Joseph A Markenson, Wilson Liao, Joseph F Merola, Jashin J Wu, JAMA

Lectures

  • Controversies and Difficult Questions Concerning Biologic Therapeutics 
    American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019

Authored Content

  • Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque PsoriasisApril 2020

Press Mentions

  • How May Biosimilars Affect the Treatment of Psoriasis?
    How May Biosimilars Affect the Treatment of Psoriasis?February 28th, 2023
  • Data Show That the Atopic Dermatitis Effects of Lebrikizumab Are Maintained
    Data Show That the Atopic Dermatitis Effects of Lebrikizumab Are MaintainedOctober 2nd, 2022
  • Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases
    Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic DiseasesSeptember 30th, 2021
  • Join now to see all

Professional Memberships